YAP activation mediates resistance to EGFR and MEK inhibition in EGFR-mutant cancer cells.
A VEGFC-expressing mRNA construct improved immunotherapy response in mouse models of glioblastoma.
Crizotinib showed efficacy in non-small cell lung cancer (NSCLC) with alterations in MET exon 14.
Drug is “super-potent” against gastrointestinal stromal tumors harboring rare driver mutation.
Novel technologies and modeling approaches are helping researchers quantify the biology of tumors.
ARID1A is required for response of ER+ breast cancer cells to tamoxifen and fulvestrant but not JQ1.
KRASG12C-mutant cells treated with KRASG12C inhibitors quickly became either quiescent or resistant.
A noninvasive test for methylated cell-free DNA markers identified colorectal cancer.
Algorithms matching the performance of expert pathologists in prostate cancer diagnosis were designed.
Claudin 6 (CLDN6) may represent a novel target for CAR-T cell therapies aimed at solid tumors.
Datasets from St. Jude and other organizations can be visualized and analyzed on cloud-based platform.
CD73hi macrophages are enriched in glioblastoma and may contribute to immunotherapy resistance.
Outer radial glia (oRG)–like glioma stem cells (GSC) were enriched in human glioblastomas.
A genome-wide association study identified two risk loci for natural killer T-cell lymphoma (NKTCL).
Overexpressing c-Jun or deleting PTPN2 improves antitumor activity, prevents exhaustion.
Drug candidates show efficacy, high response rates, in relapsed/refractory disease.
Extrachromosomal DNA drives tumor growth via chromatin remodeling and disruptive reintegration.
A mutant RAS–induced redistribution of V-ATPase to membranes mediated macropinocytosis in cells.
Nine companies join effort to amass real-world genomic and clinical cancer data and speed cancer research.
Wilms tumor–linked ENL mutations cause dysfunctional nephrogenesis and target-gene hyperactivation.
Atezolizumab plus bevacizumab better than sorafenib to treat newly diagnosed disease.
A variant of SLC1A5 (SLC1A5_var) fueled pancreatic cancer cells’ mitochondria with glutamine.
Structural and biochemical studies revealed how p27 interacts with and activates CDK4.
Updated results show longer PFS, greater brain activity for brigatinib.
Asciminib was tolerable and had preliminary evidence of efficacy in chronic myeloid leukemia (CML).
KRAS4A, but not KRAS4B, directly interacts with hexokinase 1 (HK1) on outer mitochondrial membranes.
HBO1 is required for maintenance of leukemia stem cells (LSC) in acute myeloid leukemia (AML).
Treatment with the antibiotic vancomycin to perturb gut microbiota increased radiotherapy efficacy.
E-cigarettes and vaping likely to be significant issues during his tenure.
Trastuzumab deruxtecan elicits strong responses in patients with metastatic, HER2-positive disease.
CC-486 boosts survival among older patients in remission following intensive chemotherapy.
DT2216, a proteolysis-targeting chimera (PROTAC), effectively targets BCL-XLfor degradation.
R-loop–associated genomic instability may be a therapeutic vulnerability in ETMRs.
OnlineFirst articles are published online before they appear in a regular issue of the journal. Cancer Discovery publishes two types of OnlineFirst articles.
OnlineFirst Author Manuscripts are PDF versions of manuscripts that have been peer reviewed and accepted for publication, but not yet copyedited or typeset, allowing readers the most rapid access to accepted papers. They appear on the OnlineFirst page as submitted by the authors. The Author Manuscript remains on the OnlineFirst page until it is either replaced by the final proof version or when the final version of the paper is published in an online issue.
Please note that while we strive to post all accepted manuscripts within two days of their acceptance, there may be editorial considerations, such as a planned press release or the need to coordinate posting of related articles, which may preclude or delay Author Manuscript posting.
Author Manuscripts are normally replaced on the OnlineFirst page by the final proof version of the article, which incorporates author corrections but is not yet paginated.
When papers are published in an issue, they are removed from the OnlineFirst page and appear in the appropriate issue's table of contents. The date of first publication appears below each title, followed by the article's unique Digital Object Identifier (DOI).
While an article is OnlineFirst, it may be cited as shown in the following example:
Elizabeth A. Platz et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment (April 1, 2011) Cancer Discov, 10.1158/2159-8274.CD-10-0020.
Sign up to be notified each time OnlineFirst articles are posted in Cancer Discovery.
